C4 Therapeutics Q3 2023 Earnings Report

C4 Therapeutics EPS Results

• Actual EPS: -$0.55
• Consensus EPS: -$0.65
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

C4 Therapeutics Revenue Results

• Actual Revenue: $11.07 million
• Expected Revenue: $6.94 million
• Beat/Miss: Beat by +$4.13 million
• YoY Revenue Growth: N/A

C4 Therapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/1/2023
• Time: N/A

C4 Therapeutics (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.